Disease Research Paper Assignment: Choose A Disease O 687004

Disease Research Paperassignmentchoose A Disease Or Other Condition A

Research a disease or condition affecting the systems being studied. Describe the anatomy (structure) and physiology (function) of a normal, healthy individual and compare it to an individual affected by the disease, emphasizing how homeostasis is disrupted. Incorporate relevant anatomy and physiology concepts learned in class throughout the paper. Your research should include the following sections:

Introduction – Introduce the disease with a general description, include statistics on prevalence, and mention if it occurs more frequently in specific populations.

Cause – Explain known causes such as inflammation, infection, abnormal cell growth, heredity, malnutrition, environmental factors, or stress, and how these produce signs and symptoms. Discuss prevention if applicable, or explain why prevention isn't possible.

Diagnosis – List procedures used to diagnose the disease, such as laboratory tests, imaging, biopsy, physical examinations, and patient history. Describe what signs or symptoms each procedure is looking for and connect these to the disease's cause or symptoms.

Treatment Options and Prognosis – Enumerate treatments like medication, lifestyle changes, surgery, therapy, etc., explaining how they address specific signs or symptoms. Describe typical outcomes, chances of recovery, potential permanent damage, or risk of death.

Conclusion – Reflect personally on what you learned through the research, avoiding mere repetition of facts; instead, provide a thoughtful conclusion based on your insights.

Your paper should be at least four pages, typed in 12-point font, double-spaced, with standard margins, and follow APA style. Include a title page with your paper title, name, course, section, institution, semester, and year. Use at least four credible sources, primarily scientific journals and books. Web pages like WebMD are discouraged; Wikipedia is not acceptable as a primary source but can guide other references. Plagiarism will result in a zero.

Paper For Above instruction

Introduction

Alzheimer's disease is a progressive neurological disorder characterized by memory loss, cognitive decline, and behavioral changes. According to the World Health Organization (WHO), Alzheimer’s disease affects approximately 55 million people worldwide, with the number expected to double by 2050 due to aging populations (WHO, 2021). It primarily occurs in individuals over 65, and women are more frequently diagnosed than men, possibly due to longer life expectancy (Alzheimer's Association, 2023). The disease profoundly impacts the affected individuals, their families, and healthcare systems, making it a critical public health concern.

Cause

The exact etiology of Alzheimer’s disease involves a complex interplay of genetic, environmental, and lifestyle factors. The hallmark pathological features include amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein, which disrupt neural communication and lead to neuronal death (Hardy & Selkoe, 2002). Genetic mutations in the APP, PSEN1, and PSEN2 genes have been linked to early-onset familial Alzheimer’s, while the APOE ε4 allele is a significant genetic risk factor for late-onset cases (Corder et al., 1993). Environmental factors such as cardiovascular health, diet, and physical activity influence disease risk, emphasizing the role of lifestyle in prevention. The accumulation of amyloid plaques results in neuroinflammation and oxidative stress, impairing synaptic plasticity—key to learning and memory—thus producing clinical symptoms.

Diagnosis

Diagnosing Alzheimer’s involves a combination of clinical assessments, neuropsychological testing, imaging techniques, and laboratory investigations. Magnetic Resonance Imaging (MRI) allows visualization of brain atrophy, particularly in the hippocampus and cortex, areas involved in memory and cognition. Positron Emission Tomography (PET) scans can detect amyloid and tau protein deposits, providing biomarker evidence of the disease (Jack et al., 2018). Cognitive tests, such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), evaluate memory, attention, language, and executive functions, helping differentiate Alzheimer’s from other dementias (Folstein et al., 1975). Blood and cerebrospinal fluid (CSF) analyses measure levels of beta-amyloid and tau proteins, supporting diagnostic accuracy (Hampel et al., 2018). The integration of clinical signs with biomarker data increases diagnostic confidence during the early stages of the disease.

Treatment Options and Prognosis

Currently, Alzheimer’s disease has no cure; however, several treatments aim to manage symptoms and improve quality of life. Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine enhance cholinergic transmission in the brain, alleviating symptoms related to memory and cognition (Birks, 2006). Memantine, an NMDA receptor antagonist, reduces glutamate-induced excitotoxicity, offering benefits in moderate to severe stages (Parsons et al., 2010). Non-pharmacological interventions—including cognitive stimulation, physical activity, and social engagement—support neural resilience. Recent research explores disease-modifying therapies targeting amyloid and tau pathology, but clinical success remains limited (Cummings et al., 2019).

The prognosis varies; Alzheimer’s is a progressive, irreversible disease leading to severe cognitive impairment, loss of independence, and eventually death, often within 8 to 10 years after diagnosis (Alzheimer’s Association, 2023). The disease results in a permanent loss of neuronal function and brain volume, with current treatments only slowing decline rather than reversing damage. The risk of complications such as infections and falls increases as the disease advances, contributing to mortality.

Conclusion

Through my research on Alzheimer’s disease, I have gained a profound appreciation for the complexity of this neurodegenerative disorder and its profound impact on individuals and society. Understanding the delicate balance of brain chemistry and structure, and how its disruption leads to cognitive decline, underscores the importance of early diagnosis and ongoing research for future therapies. Personally, I am struck by the challenges faced by affected individuals and the importance of supportive care and lifestyle modifications in managing symptoms. This knowledge inspires a greater awareness of the significance of brain health and the urgent need for advancements in treatment strategies to alter the course of this devastating disease.

References

  • Alzheimer's Association. (2023). 2023 Alzheimer's Disease Facts and Figures. Alzheimer’s & Dementia, 19(4), 389-469.
  • Birks, J. (2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews, (1), CD005593.
  • Corder, E., Saunders, A., Risch, N., et al. (1993). Protective effect of the apolipoprotein E type 2 allele for late-onset Alzheimer disease. Nature Genetics, 4(3), 333–336.
  • Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2019). Alzheimer’s disease drug development pipeline: 2019. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 5, 272–293.
  • Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.
  • Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356.
  • Hampel, H., O’Bryant, S. E., Castrillo, J. I., et al. (2018). Precision medicine — addressing heterogeneity in Alzheimer’s disease. Nature Reviews Neurology, 14(4), 243–255.
  • Jack, C. R., Bennett, D. A., Blennow, K., et al. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer's & Dementia, 14(4), 535–562.
  • Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356.
  • World Health Organization. (2021). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia

Related Assignments